SYRS News and Press, Syros Pharmaceuticals Inc. From 08/06/20

Syros Pharmaceuticals (NASDAQ: SYRS ) : Q2 GAAP EPS of -$0.38 beats by $0.02 . More news on: Syros Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Initiated Enrollment in Phase 1 Dose-Escalation Cohort Evaluating SY-5609 and Fulvestrant in Treatment-Resistant HR-Positive Breast Cancer Patients   On Track to Report Clinical Data for SY-1425 and SY-5609 in Fourth Quarter of 2020   Management to Host Conference Call...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Financial Officer, Joseph J. Ferra, will present a corporate overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Details are as fo...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 6, 2020 to report its second quarter 2020 financial results and provide ...

CAMBRIDGE, Mass. , July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes ther...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced a change to its presentation time at the upcoming JMP Securities Hematology and Oncology Forum. Updated details are as follows: JMP Securities Hematology an...

The following healthcare companies have filed prospectuses for mixed shelf offerings: More news on: Genprex, Inc., Syros Pharmaceuticals, Inc., ChromaDex Corporation, Healthcare stocks news, , Read more ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Hematology and Oncology Forum. Details are as follows: ...

The company in bars is, I have noticed, either very good or very bad; there seems to be some force of a minor destiny that draws good company to the same place at the same time ." - John Glassco, Memoirs of Montparnasse Today, we revisit a Tier 4 biotech concern that continues to adva...

Highly Selective and Potent Oral CDK7 Inhibitor Shows Robust Anti-Tumor Activity in Colorectal Cancer Models Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced new preclinical data for SY-5609, its highly...